A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation

NCT ID: NCT01989234

Last Updated: 2014-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

334 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This will be a multi-center, randomized, double-blind, placebo-controlled study of YKP10811 capsules in patients with chronic idiopathic constipation. Following a 2-week baseline period, approximately 320 eligible patients with \<3 complete spontaneous bowel movements (CSBM) and ≤ 5 SBMs per week will be randomly assigned equally to receive one of the following oral treatments; placebo or YKP10811 capsules once daily for 12 weeks followed by a 2 week follow-up period.

The objectives of this study are:

* To assess the efficacy of YKP10811 once daily at relieving constipation and associated symptoms in subjects with chronic idiopathic constipation.
* To determine the safety and tolerability of YKP10811 once daily in subjects with chronic idiopathic constipation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Idiopathic Constipation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Comparator

Placebo Comparator

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

YKP10811 High Dose

YKP10811 High Dose

Group Type EXPERIMENTAL

YKP10811

Intervention Type DRUG

YKP10811 Mid Dose

YKP10811 Mid Dose

Group Type EXPERIMENTAL

YKP10811

Intervention Type DRUG

YKP10811 Low Dose

YKP10811 Low Dose

Group Type EXPERIMENTAL

YKP10811

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

YKP10811

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who meet modified Rome II criteria for Chronic Constipation.
* Patients who are male or female, 18 to 65 years of age inclusive.
* At Visit 3, patients must have \< 3 CSBMs per week and ≤ 5 SBMs per week during the 2-week baseline period.

Exclusion Criteria

* Patients who meet Rome II criteria for Irritable Bowel Syndrome (IBS-C).
* Patients with constipation that is drug-induced, or secondary to endocrine, metabolic or, surgery.
* Patients with a clinically significant diseases that would limit the patient's ability to complete and/or participate in the study, including gastrointestinal disorder or surgery, an endocrine abnormality (e.g., diabetes), impaired renal function (GFR of \< 55mL/minute/1.73m2), uncontrolled pulmonary diseases (including asthma), uncontrolled cardiovascular disease (a history of myocardial infarction or cerebrovascular accident within 6 months prior to screening) or significant neurological diseases.
* Patients with a history of inflammatory bowel disease.
* Patients with a history of cancer (other than basal cell or squamous cell carcinoma of the skin completely excised) unless the malignancy has been in complete remission for at least 5 years prior to screening.
* Patients who started a special diet and/or an intense physical workout program within 30 days prior to the beginning of the baseline period or who are intending to substantially modify their dietary habits at any time during the study (patients on a stable, continuous regimen of fiber therapy for at least 30 days prior to the pretreatment baseline period are allowed to continue that therapy, provided that they continue at a constant dose throughout the study.
* Patients with a history of clinically significant hypersensitivity or allergy (facial swelling, hives, breathing difficulty, Stevens-Johnson syndrome etc), in response to any medication, either prescription or nonprescription including an investigational drug, dietary supplement, or herbal medicine.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SK Life Science, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alliance Clinical Research

Birmingham, Alabama, United States

Site Status

Clinical Research Advantage, Inc. / Warner Family Practice, PC

Chandler, Arizona, United States

Site Status

Connect Clinical Research Center

Chandler, Arizona, United States

Site Status

Clinical Research Advantage, Inc. / Central Phoenix Medical Clinic, LLC

Phoenix, Arizona, United States

Site Status

Arizona Research Center

Phoenix, Arizona, United States

Site Status

Applied Research Center Arkansas, Inc.

Little Rock, Arkansas, United States

Site Status

Digestive & Liver Disease Specialists, A Medical Group, Inc.

Anaheim, California, United States

Site Status

Precision Research Institute

Chula Vista, California, United States

Site Status

Triwest Research Associates, LLC

El Cajon, California, United States

Site Status

Diagnamics Inc.

Encinitas, California, United States

Site Status

Therapeutic Research Institute of Orange County

Laguna Hills, California, United States

Site Status

Clinical Trials Research

Lincoln, California, United States

Site Status

Alliance Clinical Research

Oceanside, California, United States

Site Status

Northern California Research

Sacramento, California, United States

Site Status

Clinical Research Advantage, Inc. / Colorado Springs Health Partners, SW

Colorado Springs, Colorado, United States

Site Status

Meridien Research

Bradenton, Florida, United States

Site Status

Palm Springs Research Institute

Hialeah, Florida, United States

Site Status

The Clinical Research Institute

Miami, Florida, United States

Site Status

Prestige Clinical Research Center Inc.

Miami, Florida, United States

Site Status

Physicians Regional Medical Group

Naples, Florida, United States

Site Status

Advanced Gastroenterology Associates, LLC

Palm Harbor, Florida, United States

Site Status

Clinical Research Trials of Florida, Inc.

Tampa, Florida, United States

Site Status

River Birch Research Alliance, LLC

Blue Ridge, Georgia, United States

Site Status

Gastroenterology Associates of Central Georgia, LLC

Macon, Georgia, United States

Site Status

Gastrointestinal Specialists of Georgia

Marietta, Georgia, United States

Site Status

North Georgia Clinical Research

Woodstock, Georgia, United States

Site Status

May Medical Center

Chicago, Illinois, United States

Site Status

Pharmakon Inc.

Evergreen Park, Illinois, United States

Site Status

Clinical Research Advantage, Inc.

Evansville, Indiana, United States

Site Status

KAMP Medical Research, Inc.

Natchitoches, Louisiana, United States

Site Status

Clinical Associates Ambulatory Surgical Center

Towson, Maryland, United States

Site Status

The Research Institute

Springfield, Massachusetts, United States

Site Status

Coastal Research Associates, Inc.

Weymouth, Massachusetts, United States

Site Status

University of Michigan Health System

Ann Arbor, Michigan, United States

Site Status

Sundance Clinical Research, LLC

St Louis, Missouri, United States

Site Status

Clinical Research Advantage, Inc.

Henderson, Nevada, United States

Site Status

AB Clinical Trials

Las Vegas, Nevada, United States

Site Status

Clinical Research Center of Nevada

Las Vegas, Nevada, United States

Site Status

Las Vegas, Nevada, United States

Site Status

AGA Clinical Research Associates, LLC

Egg Harbor, New Jersey, United States

Site Status

HBSA, A Supporting Organization of Pacific Institute for Research and Evaluation

Albuquerque, New Mexico, United States

Site Status

NY Scientific

Brooklyn, New York, United States

Site Status

Medex Healthcare Research, Inc.

New York, New York, United States

Site Status

PMG Research of Charlotte

Charlotte, North Carolina, United States

Site Status

PMG Research of Charlotte

Concord, North Carolina, United States

Site Status

PMG Research of Hickory, LLC

Hickory, North Carolina, United States

Site Status

PMG Research of Winston-Salem

Winston-Salem, North Carolina, United States

Site Status

Dayton Gastroenterology, Inc.

Beavercreek, Ohio, United States

Site Status

Consultants for Clinical Research

Cincinnati, Ohio, United States

Site Status

Hilltop Physicians IN / Hightop Medical Research Center

Cincinnati, Ohio, United States

Site Status

New Horizons Clinical Research

Cincinnati, Ohio, United States

Site Status

Columbus Clinical Research Inc.

Columbus, Ohio, United States

Site Status

COR Clinical Research, LLC

Oklahoma City, Oklahoma, United States

Site Status

Options Health Research, LLC

Tulsa, Oklahoma, United States

Site Status

Sunstone Medical Research, LLC

Medford, Oregon, United States

Site Status

The Oregon Clinic, PC - Gastroenterology West

Portland, Oregon, United States

Site Status

Clinical Trials Research Services, LLC

Pittsburgh, Pennsylvania, United States

Site Status

Partners in Clinical Research, LLC

Cumberland, Rhode Island, United States

Site Status

Health Concepts

Rapid City, South Dakota, United States

Site Status

Alpha Clinical Research, LLC

Clarksville, Tennessee, United States

Site Status

Austin Center for Clinical Research

Austin, Texas, United States

Site Status

MW Clinical Research Center

Beaumont, Texas, United States

Site Status

Houston Endoscopy & Research Center

Houston, Texas, United States

Site Status

Sun Research Institute

San Antonio, Texas, United States

Site Status

Radiant Research Inc.

San Antonio, Texas, United States

Site Status

Digestive Health Specialists of Tyler, LLP

Tyler, Texas, United States

Site Status

Advanced Research Institute

Ogden, Utah, United States

Site Status

Health Research of Hampton Roads, Inc.

Newport News, Virginia, United States

Site Status

Digestive and Liver Disease Specialists

Norfolk, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YKP10811C006

Identifier Type: -

Identifier Source: org_study_id